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1. INTRODUCTION 
Stress is defined as a state that threatens or gives the perception of a threat to a 
person’s physiological equilibrium (Weinstock, 2005). Stress is experienced when an 
individual encounters a perceived threat and undergoes the biological response that 
prepares the body for a reaction. A common term to describe this reaction is the “fight-or-
flight” response. In this response, stress from the environment activates the hypothalamus 
to release corticotropin-releasing hormone (CRH). CRH then signals the pituitary gland 
to release adrenocorticotropic hormone (ACTH), which stimulates the adrenal gland to 
release stress hormones, most notably cortisol, into the bloodstream (see Figure 1). This 
network of structures that prepares the body to react to the perception of a threat is known 
as the hypothalamus-pituitary-adrenal (HPA) axis. It is through this network that stress, 
especially when experienced chronically, is able to exert its detrimental effects on the 
body. If there is an over-activation of this system, inflammatory markers may become 
elevated, due to what is known as stress-induced immunocompromise. Elevated levels of 
inflammatory markers are associated with pathophysiologic states such as an increased 
risk for contracting infectious diseases and poor ability to heal (Stix, 2007).  
The involvement of these inflammatory markers in the experience of stress makes 
women especially vulnerable to the effects of stress, especially during pregnancy. This is 
particularly important, as there is high comorbidity between stress and depression in 
women, particularly during their reproductive years. Pregnant women undergoing high 
levels of stress or depression are increasingly vulnerable to effects such as preterm birth 
and lower birth weight of the infant. These results stem directly from the HPA axis 
activation in response to stress. Increased inflammatory response stimulates lymphocytes 
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to release cytokines, prostaglandins, and interleukins. Cytokines and prostaglandins are 
involved in controlling the contractions of uterine muscle, which may affect preterm 
labor and delivery, and cortisol released in response to stress is also closely linked to the 
process of childbirth. Most notably, cortisol is the most important modulator of the 
timing of normal parturition (Bulletins--Obstetrics, 2003). Cortisol is also involved in 
oxytocin release from the pituitary gland, which is a necessary process for the occurrence 
of the uterine contractions required for childbirth. Stress can complicate this experience 
by causing a premature release of cortisol, which could lead to preterm labor and 
delivery. This possibility depends on the stressor itself, the duration of pregnancy at the 
time of the stress, and other risk factors such as anxiety, depression, and other 
psychosocial factors (Cardwell, 2013). Due to the unique role of these hormones in 
women and the prevalence of stress and depression in women during pregnancy, it is 
necessary to study the effects of stress particularly in women and not just generalize 
findings from studies on the effects of stress in males.  
Due to the subjective nature of stress in humans and the large variety of confounds 
incorporated in human research, a rodent model to study the effects of stress on 
pregnancy and the subsequent development of the offspring is essential. In the process of 
developing this model to study development, it is first necessary to determine how best to 
administer stress to female rodents to induce a depressive-like phenotype. This goal is 
hindered by variation in the results in current research, both based on administration of 
stress and differential results between stress administered to male rodents and stress 
administered to females, making it difficult to draw conclusions.  
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There are many commonly used methods for inducing stress in rodents. Most 
frequently, these involve paradigms such as restraint stress, chronic mild stress, or cold 
stress. Stress by these methods are subject to several confounds, including variation in 
techniques between labs and individual differences in rodents between stressful 
measures. For example, one animal may be particularly sensitive to the effects of cold 
stress but less so to restraint stress. There are also several different protocols for chronic 
mild stress paradigms and each method likely produces variability in the results. 
Furthermore, rats are readily habituate to predictable stressors which means these types 
of stressors eventually do not elicit elevated levels of CORT over time (De Boer et al., 
1989; Herman, 2013).  In order to avoid these pitfalls, we decided to employ an 
alternative method of stress by administering exogenous corticosterone (CORT). 
Corticosterone is the analog to cortisol, and both are the end-products of HPA activation 
in humans and rats, respectively. Previous research has given CORT through 3 different 
administration methods: a) time-release pellet implantation, b) in the drinking water, and 
c) subcutaneous injection.  
These 3 administration methods are frequently used and well-established in the 
literature to induce a depressive-like phenotype in rodents. Interestingly, previous 
research has shown that these administration methods produce differential effects in 
females as compared to male rats (Dalla et al., 2010). While females appear to be more 
sensitive to the stressful effects of the forced-swim test than are males, females display 
less helplessness behavior in response to foot shock than do males (Dalla et al., 2008). 
The sex differences in stress response may result from the unique physiology of females 
and may be related to the female’s role as a caregiver in many mammalian species. 
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Indeed it has been hypothesized that females may have developed a different behavioral 
response to stress than males that serves to be more adaptive during their vulnerable 
states during pregnancy and nursing. Further, females have naturally higher levels of 
circulating CORT as compared to males, which may contribute to the significant sex 
difference in stress sensitivity between males and females. Due to these differences, it is 
necessary to find a method to administer exogenous CORT that is effective to develop a 
depressive-like phenotype in female rats.  
 A depressive-like phenotype in rodents has been characterized by several features: 
elevated CORT levels in blood serum, decreased body weight, an increase in immobility 
in the forced swim test, and a decrease in hippocampal neurogenesis. It has been 
hypothesized that HPA axis dysregulation is incorporated in that pathology of depression, 
and as such, is able to modulate the behavioral effects of stress. This theory is supported 
in the human literature. One study in particular demonstrated that patients suffering from 
depression whose HPA axis regulation improved after one week of pharmacological 
treatment had lower depression scores and shorter admission times compared to patients 
that continued to display HPA axis dysregulation (Schule et al., 2009). Therefore, it is 
likely that the HPA axis serves to regulate the body’s response to stress and is 
incorporated in its behavioral and physiological manifestations. As it may be impossible 
to achieve a true model of depression in rodents, the goal of this research was to mimic as 
many characteristics of the depressive-like phenotype of rodents as possible. To do this, 
this study used 3 administration routes (a) time-release pellet implantation, b) in the 
drinking water, and c) subcutaneous injection) to determine the efficacy of each in the 
development of a depressive-like phenotype in female rodents. 
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1.1. Administration by Subcutaneous Pellet 
 Time-release pellets have been used in the literature to administer CORT in 
rodents (Claflin et al., 2014; Claflin et al., 2005; Kraszpulski, et al., 2012; Murray et al., 
2008). Briefly, the rat is placed under anesthesia and the pellet is surgically implanted in 
a pocket under the skin in the lateral neck area. The pellets are designed to release a 
specific dose of CORT over 21 days before dissolving completely. In addition to the 
surgical implantation and necessity of anesthesia, another factor that must be taken into 
account with the time-release pellets is that the dose cannot be adjusted after 
implantation, i.e., for weight loss or grain. However, there are no further invasive 
procedures after the surgery and CORT is delivered at a constant dose throughout the 
testing period. Research using these pellets has demonstrated their efficacy in increasing 
CORT levels in serum, increasing immobility in the forced swim test, and decreasing 
hippocampal neurogenesis in male rodents (Murray et al., 2008). 
1.2. Administration by Drinking Water 
 While CORT has very limited water solubility, a related compound, 
corticosterone hemisuccinate, is readily water soluble and can be easily incorporated into 
a drinking water solution for administration to rodents, as demonstrated in previous 
research (Casolini et al., 207; Catalani et al., 2002; Catalani et al., 2000; Catalani et al., 
1993). This method using CORT hemisuccinate has been frequently used to study the 
effects of prenatal stress on development due to the minimally invasive nature of its 
administration (Casolini et al., 207; Catalani et al., 2002; Catalani et al., 2000; Catalani et 
al., 1993). Administration of CORT via drinking water has been shown to elevate levels 
of CORT in serum in female rats (Catalani et al., 1993; Catalani et al., 2000; Catalani et 
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al., 2003) and increase immobility in the forced swim test in male rats (Donner et al., 
2012). A consideration that needs to be made for administration via drinking water is that 
the solution will be consumed ad libitum, and as such, the dose or time of consumption 
cannot be directly controlled by the researcher.  
1.3. Administration by Subcutaneous Injection 
 Administering CORT through a subcutaneous injection has the advantage of 
being under a great deal of control by the investigator. The experimenter is able to ensure 
the exact dose is given and is able to adjust the dose in the event of weight loss or weight 
gain throughout the course of the experiment. This method has been shown effective in 
increasing immobility in the forced swim test in male rats (Hill et al., 2003) and alter 
levels of hippocampal neurogenesis (Brummelte & Galea, 2010; Mirescu & Gould, 2006; 
Wong & Herbert, 2006). A limitation of administration by injection, however, is that the 
full dose of CORT is administered at the time of the injection and is not steadily 
increased throughout the day.  
 This study aimed to evaluate the effectiveness of these 3 administration methods 
to generate a depressive-like phenotype in female rats by chronic CORT administration 
(21 days) at a dose of 40 mg/kg as used in the literature. As the majority of the literature 
on this topic is in male rats, it is critical to elucidate the most effective method for CORT 
administration in female rats. The goal of this experiment is to provide data for the future 
investigation of the effects of stress before pregnancy on development, so in addition to 
the efficacy of these methods, the levels of their invasiveness were also considered for 
future use. The measures taken were: CORT levels in serum, body weight, immobility in 
the forced swim test, and reduced levels of hippocampal neurogenesis using doublecortin 
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(DCX), which taken together are indicative of a depressive-like phenotype. To our 
knowledge, this is the first study to compare across CORT administration methods in 
female rodents on their ability to produce a depressive-like phenotype.   
2.  METHOD 
2.1.  Subjects 
Thirty-six female rats (Sprague-Dawley, age 77-84 days) were purchased from 
Charles River Laboratory (Portage, MI, USA) and were housed in a 12:12 hour light:dark 
cycle (lights on at 06:00) with food (Rodent Lab Diet 5001; PMI, Nutrition International, 
Inc., Brentwood, MO) and water available ad libitum. Animals were group-housed upon 
arrival and single-housed after a 3-day acclimation period. CORT was administered via 3 
different routes, each with a corresponding control group for which the female rats were 
randomly assigned to 1 of 6 total groups: CORT pellet (n=6), control pellet (n=6), CORT 
injection (n=6), vehicle injection (n=6), CORT in drinking water (n=6), and control 
drinking water (n=6). All animals were weighed every 3 days. 
2.2.  Hormone Preparation and Administration 
CORT or vehicle was administered for 23 days with a wean-off period from days 
21 to 23 (see Fig. 2). The wean-off period for the injection and drinking water groups was 
to mimic the potential decrease in CORT release in the implanted pellets. The dosages for 
each administration group were calculated to reflect ~40 mg/kg/day (i.e., ~10 mg/day for 
a 250 g female rat). Thus, the injection group received 40 mg/kg/day via injection. The 
pellets contained 200 mg, which was designed to be released over 21 days (200 mg/21 d 
= 9.52 mg/day; highest dose available). The dose for the drinking water (200 µg/mL) was 
based on previous studies using CORT in the drinking water with the same concentration 
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which has previously been reported to result in 13.5 ± 1.5 mg daily CORT intake 
(Catalani et al., 2002; Catalani et al., 2000; Catalani et al., 1993). An average daily water 
consumption of 30-50 mL in rats would reflect ~10 mg/day of CORT exposure (200 
µg/mL * 50 mL/day = 10mg/day; Ray & Behari, 1990; Stricker et al., 1997). 
2.2.1. Pellet Implantation 
Both CORT (#G-111, 200 mg, 21-day release) and placebo pellets (#C-111) were 
purchased from Innovative Research of America (Sarasota, FL, USA) and implanted as 
instructed by the manufacturer. Briefly, animals were anesthetized with isoflurane and 
the flow rate was maintained at a rate of 2.5-3% throughout the procedure. While the use 
of anesthesia may have been a potential limitation in these groups, it was required for the 
implantation surgery. Once deeply anesthetized, eye-lubricant was applied and animals 
received a subcutaneous injection of the non-steroidal anti-inflammatory analgesic, 
Carprofen (5 mg/kg). The surgical site was shaved and disinfected and a small incision 
(~2.5-3 cm) was made in the left shoulder area using aseptic techniques. The pellet was 
placed in a subcutaneous pocket in the lateral neck area in accordance with the 
manufacturer’s instructions. The incision site was sealed using sterile wound clips. 
Animals were weighed before being returned to a clean cage. Post-surgical monitoring 
was conducted every 5 minutes for 45-60 minutes until the animal was mobile and alert. 
Monitoring continued at less frequent intervals after the animal was returned to the 
standard housing cage and once daily for 3 weeks after surgery. Triple antibiotic ointment 
was applied to the incision site daily for 3 days following surgery and as needed after the 
third day. Wound clips were removed 7 to 10 days after the surgical procedure under 
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brief isoflurane anesthesia. As the pellets should have been fully dissolved after the 23-
day period, there was no attempt to surgically remove them at the end of this period.  
2.2.2. Subcutaneous Injection 
CORT (C2505, Sigma-Aldrich, St. Louis, MO, USA) was administered daily 
subcutaneously at a dose of 40 mg/kg. CORT was prepared fresh every 2 to 3 days by 
suspending 40 mg/ml CORT in sesame oil containing 10% ethanol. The control group 
received an injection of sesame oil vehicle alone. Ethanol was deemed unnecessary to 
incorporate into the control group, as it acts only to assist in dissolving the CORT into 
solution and would only evaporate if incorporated into the sesame oil vehicle.  Injections 
were performed between 08:00 and 10:00 for 23 days. The dose of corticosterone was 
decreased over the last injection days (days 21-d23) so that animals received 30 mg/kg on 
day 21, 20 mg/kg on day 22, and 10 mg/kg on day 23 to mimic the wean-off period that 
would be experienced with the pellet implantation.  
2.2.3. Drinking Water 
CORT hemisuccinate (#Q1562-000, Steraloids, Newport, RI, USA) was dissolved 
at a dose of 200 µg/mL in drinking water. The use of CORT hemisuccinate was necessary 
as CORT is difficult to dissolve in water.  The added salt group in  CORT hemisuccinate 
makes it readily soluble in water and its efficacy has been demonstrated previously 
(Catalani et al., 2002; Catalani et al., 2000; Catalani et al., 1993). The CORT-water was 
administered in standard drinking bottles that were wrapped in aluminum foil due to the 
potential light sensitivity of the solution.  The control group received regular tap water, 
also in bottles wrapped in aluminum foil to control for any effects of the novelty of 
aluminum foil impacting drinking behavior. All bottles were weighed daily and refilled 
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with fresh CORT or control water every 4 days or as needed. After 20 days, the dose of 
the CORT water was reduced to 150 µg/mL on day 21, 100 µg/mL on day 22, and 50 
µg/mL on day 23 to mimic the wean-off period that would be expected with the pellet 
administration.  On day 24, all injections were stopped and all animals were returned to 
normal tap water. We confirmed that all pellets were fully dissolved on the day of 
sacrifice. 
2.3. Vaginal Lavage 
All animals were lavaged on the days of testing to determine the estrus cycle 
phases. This data was used as a covariate in the analysis of the behavioral data to ensure 
that the phase of the estrus cycle did not affect behavior in the tasks. Vaginal lavage was 
performed by administering 3 to 4 drops of water into the vagina with an eyedropper and 
immediately reabsorbing the fluid with the same eyedropper. The sample was then placed 
on a glass microscope slide and stained with Cresyl Violet before the sample was dry. 
Once completely dry, each sample was examined under a microscope and the estrous 
cycle phase (metestrus, diestrus, proestrus, estrus) was determined based on the type of 
cells present as previously described (Marcondes et al., 2002; McLean et al., 2012).  This 
data was later used to control for effects of phase of the estrous cycle on behavior in the 
data analysis.  
2.4. Blood Collection and CORT Assay 
Blood samples were collected early during the CORT administration on day 3 
(d3), near the end of the administration period (d18), and a full day after being weaned 
off of the corticosterone (d25). Further, a blood sample was collected right after the first 
forced swim test session on day 20 to measure the CORT levels evoked by the test as an 
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acute stressor. Blood was collected by poking the saphenous vein with a sterile 25-gauge 
needle and allowing the sample to fall into a blood collection tube. The collection area 
was shaved the day before collection to ensure rapid blood collection that lasted less than 
3 minutes from the time the experimenter first touched the animal’s cage. CORT levels 
quickly rise in response to stress, so the 3-minute time limit ensures consistent collection 
points across animals with the stressful experience being the experimenter touching the 
cage.  All basal samples were collected in the morning between 08:00 and 10:00 to 
ensure consistency in the CORT levels by being taken at the trough of the diurnal CORT 
rhythm and kept on ice. Blood samples were allowed to clot overnight and spun down at 
8,000G for 10 minutes the next day. Serum was extracted and stored at -20C until further 
processing. Serum CORT was analyzed using a standard corticosterone EIA kit (Arbor 
Assays; Cat. # K014-H5, Ann Arbor, MI, USA) following the manufacturer’s instruction. 
2.5. Behavioral Testing 
2.5.1. Forced Swim Test 
Depressive-like behavior was assessed in the Porsolt Forced Swim Test (FST) on 
days 20, 21, and 29 as previously described (Porsolt et al., 1978). Briefly, animals were 
placed individually into a Plexiglas container (44cm deep, 30cm in diameter, Noldus 
Information Technology, Leesburg, VA, USA) filled with tap water at 25 ± 1C. The 
animal was placed in the tank for 15 minutes during the first session (d20) for habituation 
to the task, and 10 minutes for sessions 2 (d21) and 3 (d29). Session 2 was conducted at 
the end of the CORT administration period and session 3 was conducted after the 
washout from the CORT administration. All sessions were videotaped and later manually 
scored by an investigator blind to the animals’ conditions for swimming, struggling, or 
	   12	  
 
immobile behavior. The investigator would press a key on the keyboard at the start of 
each behavior and the Noldus computer software would total the duration of time spent in 
each behavior. Behaviors were defined as (1) swimming – movement of the forelimbs or 
hind limbs in a paddling fashion; (2) struggling – quick movements of the forelimbs with 
the front paws breaking the surface of the water; or (3) immobility – floating with no 
additional movement than what is required to stay afloat.  
2.5.2. Open Field Test 
The Open Field Test (OFT) was conducted on d19 to assess activity level of the 
animals. This was conducted in a circular arena with a diameter of 180cm and 50cm high 
walls (Jain et al., 2011). Movement was tracked during a 5-minute session using Noldus 
Ethovision® XT Version 7.0 software (Leesburg, VA, USA). The arena was cleaned with 
70% ethanol between animals. Measures taken were central entries, defined as entries 
into the inner circle (30cm from the wall) and overall distance travelled.  
2.6. Immunohistochemistry 
To probe for effects of the different delivery methods on hippocampal 
neurogenesis, we collected brains from all animals on d30. To do this, animals were 
deeply anesthetized with sodium pentobarbital and perfused transcardially. Following 
extraction, brains were post-fixed in 4% paraformaldehyde for 24 hours and then 
transferred to 30% sucrose in phosphate buffered saline (PBS until sectioning. Coronal 
sections (40µm) were obtained using a freezing microtome (Microm HM 450, Thermo 
Scientific, Ann Arbor, MI, USA) and stored in antifreeze until staining. Every 10th slice 
was processed for Doublecortin (DCX), an endogenous marker of new neurons. Slices 
were rinsed in 0.1M PBS overnight to remove traces of antifreeze. If not stated otherwise, 
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tissue was rinsed 3 times for 8 minutes each in 0.1M PBS between each step. Tissue was 
incubated in 0.3% hydrogen peroxide (H2O2) for 30 minutes, before being incubated in 
goat anti-DCX (0.1 M PBS, 0.5% Triton-X, 1:1000 goat anti-DCX) for 24 hours on a 
rotator at room temperature.  
The following day, tissue was incubated in biotinylated rabbit anti-goat in 0.1M 
PBS (1:200 Vector Laboratories, Burlingame, CA, USA) for 90 minutes on a rotator. 
Afterward, tissue was incubated in ABC Complex (Vector Laboratories, Burlingame, 
CA, USA) for an hour on a rotator at room temperature, before reacting with 3,3’-
daminobenzidine (DAB kit, Vector Laboratories, Burlingame, CA, USA) for 4 minutes 
using the provided Nickel from the DAB kit to enhance the staining. Tissue was mounted 
on glass microscope slides. Once dry, slides were dehydrated and then cover-slipped 
using Permount. 
2.7. Cell Counting 
Counting was performed by an experimenter blind to the animal’s group 
designation. DCX-positive cells were counted at 400x magnification. Due to the potential 
functional differences between the dorsal and ventral hippocampus, we examined the 
density of cells in both the dorsal and ventral regions separately For this, all slices on 
which the ventral portion of the dentate gyrus (DG) at the bottom of the slice was 
obviously present (-5.2 mm to -6.7 mm below Bregma according to the dorso–ventral 
coordinates of Paxinos and Watson (2005)) were considered “ventral,” while all slices 
rostral to this section were considered “dorsal,” (-1.8 mm to -5.2 mm below Bregma) as 
previously described (Brummelte & Galea, 2010). The area of the dentate gyrus was 
measured using image analysis software (ImageJ, NIH, Bethesda, MD, USA), and the 
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total volume for the dorsal and ventral portion of the DG was estimated using Cavalieri’s 
principle (Gundersen et al., 1978), i.e. by multiplying the total area measured by the 
distance between measured sections (400 µm).  Densities were calculated by dividing the 
total number of cells for each area (estimated by multiplying the total number counted by 
10, as we counted every 10th slice) by the volume of that area (dorsal or ventral).  
2.8. Data Analysis 
Repeated measures analysis of variance (ANOVA) were used to analyze body 
weight (d1, d6, d13, d20, and d23 of CORT administration as within-subject factors), 
immobility in the FST (sessions 2 and 3 as within subject factors), volume of the dentate 
gyrus, and density of DCX-positive cells (dorsal and ventral as within subject factors). 
Treatment (control, CORT) and administration route (injection, pellet, drinking water) 
were treated as the between-subjects factors. Further, factorial ANOVAs with treatment 
(control, CORT) and administration route (injection, pellet, drinking water) as the 
between-subjects factors were performed to analyze body weight on d30, serum CORT 
levels taken on d3, d18, d25, and after the FST on d20, and open field test behaviors for 
anxiety-like behavior. After initial analysis, estrous-cycle phase was added as a covariate 
to the analysis to test whether it had an impact on the reported group differences. All 
post-hoc tests utilized Fisher LSD. Data was analyzed using STATISTICA (Statsoft, 
Tulsa, OK, USA). 
3.  RESULTS 
3.1  Body Weight 
A factorial repeated-measures ANOVA revealed no main effect of CORT 
treatment or route (p > 0.11, for both). There was, however, a significant interaction of 
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CORT treatment and administration route (F(2,26) = 3.95, p < 0.03), as well as an 
interaction of days and CORT treatment (p < 0.001), and days and administration route (p 
< 0.04). An LSD post-hoc test further revealed that these interaction effects were due to 
the CORT injection group, which had significantly lower body weight compared to their 
control group (p < 0.004) and compared to the other 2 CORT treatment groups (p < 0.04). 
Looking at the post-hoc results by day revealed that this lower body weight began on d6 
(p < 0.04) of CORT administration and continued throughout the rest of the experiment 
with the difference between the groups increasing towards d23 (p < 0.001) (see Fig. 3A). 
  Body weight on the day of perfusions (d30) was analyzed with a factorial 
ANOVA, as the wash-out period between d24 and d30 would disqualify this measure 
from being incorporated in the repeated-measures ANOVA. This analysis specifically 
assessed whether or not the difference in body weight remained constant between groups 
after the wash-out period. The factorial ANOVA for body weight on d30 revealed a 
significant CORT by administration route interaction effect (F(2,23) = 4.84, p < 0.02). A 
LSD post-hoc test revealed that this effect was driven by the CORT injection group, 
which still had lower body weight compared to all other groups (p < 0.04), except the 
water control group (p < 0.06) (see Fig. 3B). 
3.1.1. Water Intake 
There was no difference in average daily water intake between the 2 groups 
receiving either normal tap water or CORT in their drinking water (p < 0.38, No CORT: 
39.06mL ± 1.5mL; CORT: 40.97mL ± 1.4mL). This amount of daily water consumption 
means that animals received only ~8mg of CORT daily (40ml* 200µg/ml = 8mg).  
3.2 Serum CORT Levels 
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Serum CORT levels were analyzed separately for each collection time point (d3, 
d18, and d25) with factorial ANOVAs, as day 25 was after the wash-out period, and due 
to the fact that CORT levels can vary substantially between days due to environmental 
circumstances. The use of factorial ANOVAs aided in reducing any confounds created by 
intermittent behavioral testing on CORT serum levels. On d3 there was a significant main 
effect of treatment (F(1,28) = 150.2; p < 0.001) and route of administration (F(2,28) = 
85.1, p < 0.001), and an interaction effect of CORT and route (F(2,28) = 80.8, p < 0.001). 
The post-hoc test revealed that the CORT pellet and injection groups had significantly 
elevated levels compared to their own and all other vehicle groups (p’s < 0.001). 
Interestingly, the CORT-water group had similar levels to all the control groups (p < 
0.37).  
 On d18 there was a significant effect of route (F(2,22) = 11.76, p < 0.001) and 
treatment (F(1, 22) = 9.23, p < 0.006), and an interaction effect of route and CORT 
treatment (F(2,22) = 14.53, p < 0.001). The post-hoc test showed that only the injection 
group had significantly elevated CORT levels compared to all control groups (p’s < 
0.001).  
On d25, one full day after the last reduced dose CORT administration, there was a 
significant interaction effect of route and CORT treatment (F(2,23) = 4.22, p < 0.027), 
but no significant main effect. The post-hoc test revealed that the injection group had still 
slightly higher CORT levels compared to their control group (p < 0.01) (See Fig. 4).  
CORT levels were analyzed in response to the stress of the first swim test session 
(d20). The factorial ANOVA revealed a significant main effect of treatment (F(1,26) = 
19.5, p < 0.001) and route of administration (F(2,26) = 4.1, p < 0.028), but no interaction 
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effect. Post-hoc tests showed that CORT-treated animals had significantly lower stress 
CORT levels than their controls (pellet: (p < 0.04), water: (p < 0.01), injection: (p < 
0.007)).  We repeated the analysis and included the estrous cycle phase for the first FST 
session to control for potential variation in stress CORT levels due to the estrous phase, 
however, the estrous cycle phase was a non-significant covariate (p < 0.87) and did not 
impact the significant effects (See Fig. 5). 
3.3 Forced Swim Test Behavior 
Animals were tested in the FST at the end of the CORT administration period 
(d20/21) and again 6 days after weaning off the CORT (d29). A repeated measures 
ANOVA with time spent immobile in FST 2 and FST 3 as the within subject factor 
revealed a significant CORT by route of administration interaction effect (F(2,26) = 9.5, 
p < 0.001) and a significant effect of the test session (F(1,26) = 11.3, p < 0.002), with 
animals being generally more immobile in the third compared to the second FST session. 
The post-hoc test further showed that CORT injection animals spent significantly more 
time immobile compared to their vehicle control (p < 0.001). Further, the CORT in 
drinking water group spent significantly less time immobile compared to their control 
group (p < 0.02). However, this may be an alpha error as the water control group had 
significantly higher immobility scores compared to the other 2 control groups (p < 0.04 
and 0.006, respectively; See Fig. 6).   
To account for variability in FST performance due to estrous-cycle phase, we 
repeated the analysis separately for each session while including the estrous-phase as a 
co-variant. The estrous cycle was a non-significant contributor to FST 3 performance (p < 
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0.98). However, estrous cycle was a significant co-variable in the FST 2 immobility 
scores analysis (p < 0.002), but with no effect on the main outcomes.  
3.4. Open Field Test 
There was no significant difference for treatment or route of administration for the 
distance travelled in the open field between the groups (all p’s > 0.19), nor was there a 
difference in the time spent in the center (all p’s > 0.07; See Table 1).  
3.5. Neurogenesis in the Dentate Gyrus 
A repeated-measures ANOVA (controlling for the estrous cycle) revealed no 
significant main effects of treatment (p < 0.90), route (p < 0.69), or their interaction (p < 
0.21), and no effect by area (dorsal versus ventral; all p’s > 0.21) for the density of DCX-
positive cells (Table 2). Also, the estrous cycle did not significantly impact these results 
(p < 0.68) as almost 80% of the animals were either in estrus or pro-estrus at the time of 
sacrifice.  
4.  DISCUSSION 
The present study is the first to compare methods of administering exogenous 
CORT in female rodents on their efficacy in producing a depressive-like phenotype. It 
was found that CORT via injection alone was able to produce an increased level of 
CORT in serum, decreased body weight, and increased immobility in the forced swim 
test. None of the methods investigated impacted hippocampal neurogenesis. Results from 
the present study indicate that body weight, CORT serum levels, and FST behavior were 
very different depending on the method used for CORT administration. Female rats that 
were administered CORT through injections weighed less, were more immobile in the 
FST, and had the highest CORT serum levels, which is consistent with previous 
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publications (Brummelte & Galea, 2010; Gregus et al., 2005). Conversely, animals that 
received CORT in their drinking water or through subcutaneously inserted 21-day release 
pellets showed no significant weight loss or increased immobility in the FST.  Only the 
pellet group had transiently increased serum levels of CORT that returned back to normal 
on day 18.  
4.1 Route of CORT Administration Affects Body Weight  
Starting on the 6th day of CORT administration, injection animals weighed less 
than their controls and this difference remained significant until the last day of the 
experiment, even after the animals were weaned off the CORT. This effect is consistent 
with previous reports on reduced body weight after CORT injections (Brummelte et al., 
2006; Gregus et al., 2005). However, we did not observe significant reductions in body 
weight in the CORT pellet or drinking water group. Previous studies using CORT in the 
drinking water found that male animals receiving CORT via drinking water at 40 and 100 
µg/mL displayed significantly less weight gain as compared to control groups while 
animals receiving 400 µg/mL showed significant weight loss compared to control 
animals (Donner et al., 2012; Pekary et al., 2008). Similarly, several previous studies 
using CORT pellets have reported some reductions in body weight (Claflin et al., 2005). 
This apparent discrepancy with our results may be due to the fact that we used only 
females in our study. Females are known to have naturally higher circulating CORT 
levels and adult females do not show the continued significant weight increases observed 
in males. Thus, CORT delivered by drinking water to the female rats in our study may 
not have been as effective in altering body weight as it is males.  For the pellet group, 
there was a trend for reduced body weight on day 6 which became significant if the pellet 
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group was analyzed separately without the injection group included in the analysis. It is 
not surprising that this effect disappears after day 6, as it seems that all CORT may have 
been released from the pellet too early. 
 The larger effect of CORT on body weight when given via injection correlates 
with the higher serum levels observed in this group. The ability of stress to exert 
physiological effects through the HPA axis could result in this observed reduced body 
weight and decreased weight gain. Interestingly, s.c. injections of 10mg/kg led to 
significantly elevated CORT serum levels and reduced body weight in males in a 
previous investigation, but non-significant changes in females in the present 
investigation, again suggesting that females are less sensitive to lower levels of CORT 
(Brummelte & Galea, 2010). This highlights the importance of taking sex differences into 
account as many studies have investigated the effects of chronic CORT exposure in only 
males (Bush et al., 2003; Gregus et al., 2005). 
4.2 Different Administration Methods Lead to Varying CORT Serum Levels  
Rats in the injection group had elevated CORT levels on days 3 and 18 of the 
experiment, while animals in the drinking water group did not reveal any alterations in 
basal CORT levels during the administration period. Animals that received CORT pellets 
had higher CORT serum levels 3 days after the implantation, but levels were back to 
baseline on day 18. All doses were originally calculated to reflect ~10mg of CORT per 
day; however, there were certain limitations on ensuring that all groups received exactly 
the same amount of CORT. The pellet animals received ~9.5mg per day if the pellet 
released CORT at a constant rate, while the drinking water group ended up taking in 
~8mg a day based on ~40mL of water intake per day. Further, with the 21-day release 
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pellets and CORT in the drinking water, it is impossible to adjust the dose of CORT 
given for weight changes in the animals during the experiment. All but the CORT 
injection group continued to gain weight throughout the experiment, so that by the last 
day of CORT administration animals in these 2 groups may have received less CORT per 
body weight than they received in the beginning. These slightly lower doses in the pellet 
and water group and the unintentional but unavoidable tapering off of the dose due to 
increasing body weight, may partly explain why these animals had lower serum 
concentrations and seemed better adjusted to the CORT treatment.  
Our study was designed to compare the different administration methods of 
CORT exposure as well as compare our results to previously used doses in other studies 
investigating the developmental effect of CORT exposure (Catalani et al., 2002; Catalani 
et al., 2000). These papers reported serum levels of 4.3 ± 0.5 to 9.5 ±1.8µg/100mL 
(equivalent to 43-95ng/mL) after 200µgl/mL in the drinking water in postpartum female 
rats (Catalani et al., 1993). These levels are within the normal range of basal CORT 
serum levels for adult females, and thus in line with our findings in the present study of 
similar CORT levels in control and CORT water females. This effect was also displayed 
in male rats at doses varying from 25µg/L to 400µg/L, where CORT levels in serum were 
only elevated at the 400µg/L, but not at 25µg/L (Pekary et al., 2008). Other studies using 
400µg/mL of CORT in drinking water for 21 days in males reported significant increases 
in morning CORT levels, but not beyond the natural evening peak in CORT (Magarinos 
et al., 1998). These studies collectively are in agreement with our finding in the present 
study that CORT administered via drinking water did not significantly increase CORT 
levels in serum. It should be noted that the drinking water group in the present study 
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received CORT hemisuccinate, instead of CORT, which does not go into a water-based 
solution as easily. The use of CORT hemisuccinate versus CORT may have also 
contributed to the lower serum levels observed in the present group. Also, the timing of 
blood collection (early morning, in this study) compared to the peak drinking time of the 
animals (beginning of dark cycle) may explain why increases in CORT serum levels are 
not consistently found across studies using water drinking administration.  
The pellet group displays elevated CORT serum levels on day 3, but these levels 
were less than half the CORT serum levels of the injection group. The fact that the CORT 
serum levels were back to normal by day 18 indicates that the pellets may have released 
its contents earlier than the 21-day period. This idea is in line with previous studies that 
have found similar effects with these pellets releasing most of their CORT within a few 
days rather than over the period of 21 days (Claflin et al., 2014; Claflin et al., 2005; 
Kraszpulski, et al., 2012; LaPlante & Tomaszyki, 2012). However, it is possible that 
these results may be specific to the brand of pellet that was used and other pellets may be 
more reliable in their delivery.  
Interestingly, all 3 CORT groups revealed lower stress-induced CORT levels after 
the FST on day 20 as compared to the control groups. This indicates that even the groups 
that did not show measurable increases in baseline CORT levels experienced alterations 
in HPA axis functioning in response to the exogenous CORT administrations. The fact 
that CORT levels were lower may suggest that the animals down-regulated their 
endogenous CORT production as a consequence of the excess amount of exogenous 
CORT circulating in their systems. All groups were still able to mount a stress-induced 
response, though the magnitude was lower in the injection group, probably due to the 
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already high baseline levels. These results agree with previous research showing that high 
levels of CORT are able to alter HPA axis function (Dallman et al., 1994).  For instance, 
exposing rats to a series of acute stressors for 14 days resulted in reduced HPA response 
following acute immobilization stress on day 15 (Roth et al., 2012). 
One limitation of our study is that we did not measure levels of Corticosteroid-
binding globulin (CBG). While only free CORT is biologically active and can induce 
effects in the body, serum CORT levels reflect the total amount of CORT (i.e., free and 
CBG-bound CORT). We cannot exclude the possibility that the CORT-treated animals 
up-regulated their CBG levels to bind most of the excessive CORT. However, the fact 
that we did observe behavioral (FST) and body weight changes in at least the injection 
group, suggests that the elevated total levels of CORT did have an impact on the animals’ 
brain and behavior.  Another potential limitation is that only one dose of CORT was used 
in this study. However, this dose has been frequently and successfully used in the 
literature, so we don’t think this is a major limitation in this study. Another limitation in 
this study is the inconsistent delivery of CORT in the CORT pellet group. It seems that 
the pellets released too much CORT too soon and had stopped working before the end of 
the experiment, as evidenced by the CORT levels in serum which were only significant at 
the first time point. It is also noteworthy that the rats receiving the CORT placebo pellets 
developed fluid-filled seromas around the site of the pellet which may have impacted 
their body weight. A valuable future direction may include repeating the study with the 
inclusion of males or a different brand of pellets to test the theory that some of these 
methods are effective in males at similar doses, but less so in females.  
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4.3. Only Injections of CORT Resulted in Increased Immobility in the Forced Swim 
Test 
High levels of CORT have repeatedly been shown to induce depressive-like 
behavior in the FST in males and females (Galea et al., 2008; Gregus et al., 2005; Hill et 
al., 2003). However, this was only evident if using sufficiently high doses. For instance, 
10mg/kg of CORT s.c. injections into postpartum dams did not increase immobility 
levels in female rats (Brummelte et al., 2012) whereas 20mg/kg per day for 20 days 
increased immobility in males, but not female rats (Hill et al., 2003). 
Similar results to this study have been previously reported for chronic CORT 
administered via pellet implantation. Male mice implanted with CORT pellets showed an 
increase in immobility in the FST 7 days after implantation, but this effect was abolished 
by days 14 and 21 (Murray et al., 2008).  Studies administering CORT via drinking water 
demonstrated an increase in immobility in the FST at doses of 100 and 400µg/mL after 
18 days of CORT treatment. However, this study utilized exclusively male rats and these 
results may reflect sex specific differences in CORT-sensitivity and behavior in the FST 
(Donner et al., 2012). One study using 80ug/ml CORT in drinking water of female mice 
failed to demonstrate differences in immobility in the FST based on CORT 
administration, further emphasizing the importance of assessing females in the FST 
(Zoratto et al., 2011). Thus, it is conceivable that females need higher levels of 
circulating CORT before their FST performance is affected, which may explain why we 
only saw an effect in our injection group that had significantly higher serum 
concentrations than the other groups.  
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4.4. Chronic CORT Administration Did Not Alter Neurogenesis Levels 
A growing body of research indicates that heightened levels of stress or CORT in 
rodents can change levels of neurogenesis in the brain (Brummelte & Galea, 2010; 
Mirescu & Gould, 2006; Wong & Herbert, 2006). For example, previous work has shown 
that 40mg/kg of CORT led to slightly fewer Ki67-positive and DCX-positive cells in the 
ventral dentate gyrus of females rats, while the same dose led to fewer DCX-positive 
cells in the ventral and dorsal hippocampus of male rats (Brummelte & Galea, 2010).  
Surprisingly, none of the CORT-treated groups in the current study showed any 
alterations in the number of DCX-positive cells in the dentate gyrus. However, it should 
be mentioned that the previous study measures were taken immediately after the last day 
of injections while in the current study, females were weaned off the CORT for 3 days 
and sacrificed a week after the last reduced dose injection. The wean-off period in the 
present study was deemed necessary as the subcutaneous pellet would have a slow decay 
in CORT release and this effect needed to be mimicked in the other groups for 
consistency. Thus, neurogenesis levels may have recovered and returned to normal by the 
point we took measurements. In a previous study a lower dose of CORT via s.c. injection 
(10mg/kg) did not result in altered cell proliferation or neurogenesis levels (Brummelte & 
Galea, 2010) consistent with our current finding of no difference in the water or pellet 
group. However, there may be other changes to the hippocampal structure as others found 
that 21 days of 400µg/mL of CORT in the drinking water led to reduced apical dendrites 
in the CA3 region and reduced number of DCX-positive cells in the piriform cortex layer 
II (Magarinos et al., 1998; Nacher et al., 2004).   
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Other studies focusing on the effects of CORT administration via pellet implantation on 
hippocampal neurogenesis have demonstrated that a 100mg CORT pellet was able to 
significantly reduce hippocampal neurogenesis after 21 days of implantation, which 
remained significant after a 7-day washout on day 28 (Murray et al., 2008). This study 
did measure CORT levels in serum at day 21, and saw a significant effect of CORT pellet 
implantation on CORT in serum, and also measured CORT levels at day 28 after a seven-
day washout period where this effect was abolished. These results may differ from those 
of the present study due to the fact that in our study, CORT serum levels were not 
significantly elevated 18 days after pellet implantation. Thus, our animals had plenty of 
time to regain normal levels of neurogenesis by day 30 when they were sacrificed. The 
study (Murray et al., 2008) demonstrating significant differences in levels of 
neurogenesis may have utilized pellets that did not release their content entirely before 
the end of the 21-day period, as is theorized ours may have.   
Significant sex differences exist in the effects of CORT administration or stress 
on neurogenesis levels. For example, adult males show diminished cell survival in 
response to chronic stress, whereas the same stressors in females demonstrate enhanced 
cell survival, further demonstrating the sex-specific effects of stress on hippocampal 
neurogenesis in adulthood (Kuipers et al., 2006). These studies suggest that we cannot 
generalize findings from males to females and need to pay particular attention to the 
unique physiology of females that may result in different or opposite effects of stress and 
corticosterone. 
4.5 Considerations for Choosing a CORT Administration Method 
	   27	  
 
Overall, CORT pellets and water administration were less controllable methods in 
regards to managing the CORT dose, but even if the final dose in these 2 groups was 
slightly lower than anticipated (due to less water intake or weight gain), it does not 
account for the drastic difference in CORT serum levels between these groups and the 
CORT injection group. More likely, the different pharmacokinetics involved with each 
administration method may play a role. The absorption and distribution of CORT from an 
oral route will be much slower and probably less effective compared to subcutaneous 
administrations, which may explain why the water group seems to be the least affected by 
the CORT treatment. Further, the timing and the natural diurnal rhythm of CORT are 
essential considerations. While the pellets provide a supposedly constant supply of 
exogenous CORT, the injections deliver one acute burst in increased CORT levels per 
day, and the drinking water dose results in varying amounts depending on the water 
consumption during a given day.  Considering that the artificially increased amount of 
CORT in the system will lead to some form of HPA axis reprogramming or adjustment, it 
is conceivable that the HPA axis reacts to each delivery method differently.  
Taken together, our least preferred administration method were the subcutaneous 
pellets, as they were apparently not reliable in their release pattern. This could however 
have been specific to the brand of pellet we used, as others have reported no such issues 
(Claflin et al., 2014, Claflin et al., 2005). We also had some trouble with wound healing 
in 3 animals of the CORT pellet group, and all of the placebo pellet rats developed a 
fluid-filled pocket around the implant several days after the implantation, which led to the 
exclusion of some of these animals from the study. None of the animals had infected 
incision sites or any indication that this was caused by the surgical procedure according 
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the veterinarian consult, who further confirmed that the complications were unlikely due 
to surgical complications, as only the placebo animals developed seromas, while the 
CORT pellet group had trouble with wound healing. The extra fluid may also explain the 
temporary weight gain seen in the placebo pellet animals between days 6 and 9. Besides 
that, the placebo pellet animals looked very similar to the other 2 control groups in most 
measures, suggesting no significant impact of these complications on our measures.  
To our knowledge, this is the first study to compare CORT levels by 
administration route in female rodents. The results confirm previous studies that only 
high CORT levels in serum reduce FST behavior and body weight, but neurogenesis 
levels seem to recover after a washout period. This study enables us to better understand 
how CORT levels are impacted by administration route, and we plan to use this to further 
investigate the effects of CORT administration during pregnancy on the development of 
the offspring. This study also indicates the necessity of verifying CORT levels in the 
system after administration regardless of administration route.  
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 There is wide variation in the current literature on rodent models of high levels of 
chronic stress. This study aims to reduce these discrepancies by investigating the effects 
of 3 different administration methods of corticosterone (CORT; the endogenous stress 
hormone in rodents) and the differential effects it has in the female sex. The majority of 
studies utilize male rodents, while research in female rodents is largely under-
investigated. This study will utilize female rats and 3 different administration routes: a) 
subcutaneous implantation of a CORT pellet, b) CORT in the drinking water, and c) 
CORT by a daily subcutaneous injection, and assess its impacts on CORT levels in 
serum, depressive-like behavior, and levels of hippocampal neurogenesis. This study will 
enable researchers to better understand the effects of chronic CORT exposure in female 
rodents, as well as reduce the variation in current literature on the effects of CORT based 
on administration route. 
  
	   36	  
 
AUTOBIOGRAPHICAL STATEMENT 
 
Jennifer Kott is currently a student in Wayne State University’s Psychology 
department with a major in Behavioral and Cognitive Neuroscience. She is minoring in 
Psychopharmacology. She got her Bachelor of Science degree in Psychology from 
Michigan State University in 2011. She is currently working under the supervision of Dr. 
Susanne Brummelte to further her research and academic career studying the effects of 
adverse early life experience on development.  
  
	   37	  
 
Figure 1 
 
 
Source: http://soundersleep.com/hpa.php 
 
 
Figure 1. Diagram of the hypothalamic-adrenal-pituitary (HPA) axis.  
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Figure 2                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overview of the experimental procedures. CORT will be administered for 21 
days followed by a wean-off period before sacrifice. Behavioral testing including the 
forced swim test and the open field test will occur throughout the experiment, and blood 
will be collected at several time points. OFT: Open Field Test, FST: Forced Swim Test, 
CORT: corticosterone 
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Figure 3 
 
 
 
Figure 3. (A) Animals receiving CORT injections had significantly reduced body weight 
compared to all other groups beginning on the 6th day of treatment and continuing 
throughout the experiment. (B) Animals receiving CORT injections still had significantly 
reduced body weight compared to all groups except for the water control group on the 
day of perfusions *p < 0.05, ***p < 0.001 compared to all other groups. ♮p < 0.05 
compared to all groups except water control group. 
  
	   40	  
 
Figure 4 
 
 
Figure 4. Serum CORT levels at different time points throughout the experiment 
On day 3 of CORT administration, the CORT pellet and CORT injection group had 
significantly elevated levels of CORT compared to all vehicle groups. On day 18, this 
effect held true for only the CORT injection group. On day 25 of CORT administration, 
only the CORT injection group displayed significantly elevated levels of CORT 
compared to its own control group. #p < 0.001, *p < 0.01 compared to its own control 
group.  
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Figure 5 
 
Figure 5. Shown are the CORT levels on d20 after the FST.  CORT levels were 
significantly lower in each CORT-treated group compared to its respective control group 
*p < 0.05. 
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Figure 6 
 
Figure 6. In both FST sessions, animals that received CORT via injection spent 
significantly more time immobile compared to their control group. Animals that were 
administered CORT in the drinking water spent significantly less time immobile 
compared to their control group. *p < 0.05 compared to their own control groups.  
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Table 1 
Open	  Field	  Test	  
	   	  	  	   	  	   	  	  
	  	   Total	  Distance	  (cm)	   Duration	  in	  Center	  (s)	  
	   	   	  Control	  Pellet	   4440.26 ± 504.21 38.17 ± 11.37 
Control	  Water	   4128.36 ± 461.29 33.23 ± 8.58 
Control	  Injection	   4473.52 ± 292.03 28.35 ± 4.56 
CORT	  Pellet	   5141.64 ± 355.83 55.73 ± 13.53 
CORT	  Water	   4701.78 ± 352.49 28.06 ± 5.73 
CORT	  Injection	   4545.02 ± 345.66 25.64 ± 6.15 
	  	   	  	   	  	  
	   	   	  Mean	  ±	  S.E.M.	  
	   	   
Table 1. Shown are the effects of CORT on the open field test.  No significant differences 
were observed in the distance travelled or time spent in center between treatment groups 
or route of transmission. 
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Table 2 
Hippocampal	  Neurogenesis	  (DCX	  Density)	  
	  	  	   	  	   	  	  
	  	   Dorsal	   Ventral	  
	   	   	  Control	  Pellet	   8199.29 ± 924.252 6255.391 ± 972.212 
Control	  Water	   8989.381 ± 1044.423 6694.054 ± 944.081 
Control	  Injection	   7693.381 ± 760.394 5777.204 ± 591.506 
CORT	  Pellet	   8757.175 ± 668.111 8398.541 ± 475.372 
CORT	  Water	   7518.803 ± 702.397 
5191.190 ± 
1078.961 
CORT	  Injection	   8519.247 ± 769.592 5303.460 ± 582.210 
	  	   	  	   	  	  
	   	   	  Mean	  ±	  S.E.M.	  
	   	   
Table 2. Shown are the effects of CORT on hippocampal neurogenesis.  No significant 
differences were observed by treatment, route, the interaction of treatment and route, or 
difference between areas in hippocampal neurogenesis. 
 
